GeneCentric's Cancer Subtyping Platform (CSP®)

Our initial approach to developing universal drug response biomarkers is based on the CSP® technology we developed for generating high resolution, genomic-defined cancer subtypes.

These unique genomic profiles are designed to characterize tumor biology in a manner that enables optimal targeting of therapeutic compounds. The CSP profilers combine gene expression data with disease-related molecular pathways and immune cell expression to identify therapy response signatures using advanced computational biology technologies.

LEARN MORE

Our Growing Portfolio of Cancer Profilers

GeneCentric is building a pipeline of universal cancer subtypes/biomarkers for the most prevalent and complex cancers. Profilers are currently available in the areas of lung cancer – the leading cause of cancer deaths in the U.S. – and head and neck cancer.

LEARN MORE

Achieving Greater Progress Through Effective Collaboration

GeneCentric is proud to collaborate with some of the world’s leading research and development organizations. By bringing together our unique strengths and proprietary technology with that of our partners we are able to rapidly and efficiently translate the most promising science and advance drug development, delivering new hope to those fighting cancer today.

LEARN MORE

GeneCentric Adds Unique Value at Every Stage of Drug Development

Development Stage Involvement

Drive translational research to FIM through novel in-silico and in-vivo modeling

Enable clear segmentation of patients via subtyping during early drug development

Confirm subtype profilers as response biomarkers supporting accelerated drug, and companion diagnostic, development

Expand subtypes drug-response biomarkers in confirmatory and indication expansion studies to maximize market potential

Reposition and repurpose drugs by subtyping patients to reveal new or additional drug responder populations and commercial potential

Making News: Our Latest Progress, Partnerships and Impact

GeneCentric Therapeutics Announces Research Collaboration on Drug Response Biomarkers for Lung Cance ...

LEARN MORE

GeneCentric Therapeutics CEO and Founder Dr. Myla-Lai Goldman to be featured on ”Radio In Vivo: Yo ...

LEARN MORE

Differences in BRCAness/PARP Inhibitor Response Signatures and Homologous Recombination Gene Express ...

LEARN MORE